Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
MJ Elliott, RN Maini, M Feldmann, A Long-Fox… - The Lancet, 1994 - Elsevier
MJ Elliott, RN Maini, M Feldmann, A Long-Fox, P Charles, JA Bijl, JN Woody
The Lancet, 1994•ElsevierOur in-vitro, animal, and early clinical data suggest that tumour necrosis factor α (TNFα) is an
important target for specific biological therapy in rheumatoid arthritis. We report the results of
repeated treatment with a chimeric monoclonal antibody to TNFα (cA2) in patients having
disease flares. 7 patients originally enrolled in an open-label trial completed two to four
cycles, each of which was followed by a good clinical response, with median improvements
in the swollen-joint count and C-reactive protein exceeding 80%. cA2 may be useful therapy …
important target for specific biological therapy in rheumatoid arthritis. We report the results of
repeated treatment with a chimeric monoclonal antibody to TNFα (cA2) in patients having
disease flares. 7 patients originally enrolled in an open-label trial completed two to four
cycles, each of which was followed by a good clinical response, with median improvements
in the swollen-joint count and C-reactive protein exceeding 80%. cA2 may be useful therapy …
Abstract
Our in-vitro, animal, and early clinical data suggest that tumour necrosis factor α (TNFα) is an important target for specific biological therapy in rheumatoid arthritis. We report the results of repeated treatment with a chimeric monoclonal antibody to TNFα (cA2) in patients having disease flares. 7 patients originally enrolled in an open-label trial completed two to four cycles, each of which was followed by a good clinical response, with median improvements in the swollen-joint count and C-reactive protein exceeding 80%. cA2 may be useful therapy in the control of acute disease flares in rheumatoid arthritis and treatment programmes including cA2 may be effective in the long-term management of this disease.
Elsevier
